Immunic Inc. Stock
Immunic Inc. Stock
A loss of -1.250% shows a downward development for Immunic Inc..
Our community is currently high on Immunic Inc. with 6 Buy predictions and 3 Sell predictions.
Based on the current price of 1.25 € the target price of 5 € shows a potential of 298.72% for Immunic Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Immunic Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Immunic Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Immunic Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Immunic Inc. | -1.250% | 7.511% | 3.794% | -18.043% | -13.916% | -89.541% | - |
| Ocuphire Pharma Inc. | 2.500% | 14.570% | 0.000% | -69.272% | -38.104% | - | - |
| NanoViricides Inc. | -1.940% | 0.000% | -21.705% | -7.339% | 6.878% | -67.957% | -75.895% |
| Synthetic Biologics Inc. | 1.050% | - | - | - | - | - | - |
Comments
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for IMUX provided by MarketBeat